The effectiveness of gabapentin in treating overactive bladder: a quasi-experimental study

Author:

Ayyad Malik1ORCID,Ayaad Omar2ORCID,Alkhatatbeh Hassan3ORCID,Sawaqed Fadi4,Al-Rawashdeh Samer1,Qaddumi Bayan5

Affiliation:

1. Department of Urology Unit Special Surgery, Faculty of Medicine Mutah University Karak, Jordan

2. Sultan Qaboos Comprehensive Cancer Care and Research Center, Muscat, Oman

3. Department of General Surgery, Urology and Anaesthesia, Faculty of Medicine, Hashemite University, Zarqa, Jordan

4. Department of Special Surgery, Faculty of Medicine, Mu’tah University, Karak, Jordan

5. King Hussien Cancer Center, Amman, Jordan

Abstract

Introduction: Overactive bladder (OAB) is a common condition in urology that affects individuals of various ages and genders, significantly impacting their quality of life. Objectives: The study aimed to examine the effectiveness of gabapentin in treating OAB in Jordan. Patients and Methods: This study was conducted at a private clinic in Jordan between 2020 and 2022. It utilized a one-group pre- and post-test design involving 50 patients. The intervention involved administering gabapentin at a daily dose of 400 mg. The effectiveness of gabapentin was evaluated using the overactive bladder symptom score (OABSS) questionnaire, administered before and after six weeks of gabapentin administration. Results: The study sample consisted of 50 patients aged between 45 and 85 years, with a mean age of 65.2 years. After the treatment, all individual variables, such as urgency, frequency, nocturia, and urgency incontinence, showed significant reductions compared to the pre-intervention values. The mean total OABSS significantly decreased from 14.6 before to 6.8 after the intervention. The paired t test yielded a result of 9.84 with a P value of less than 0.001, indicating a statistically significant improvement. Conclusion: The noteworthy improvement in OABSS scores, urgency, nocturia, frequency of micturition, and urge incontinence observed in this study suggests that gabapentin could have a role as a treatment option for OAB patients.

Publisher

Maad Rayan Publishing Company

Subject

Immunology and Microbiology (miscellaneous),Hematology,Immunology,Endocrinology, Diabetes and Metabolism

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3